

Jonathan Z. Rosenbluth, MD, MPH
Regional Cancer Care Associates – Somerset Division
30 Rehill Avenue, Suite 2500
Somerville, NJ 08876
(908) 927-8700 *rosenbj1@yahoo.com*

Professional

Hematologist-Oncologist, Regional Cancer Care Associates – Somerset Division,
formerly Somerset Hematology Oncology Associates, 1/2008-Present

- Privileges at Somerset Medical Center in Somerville, NJ and JFK Medical Center in Edison, NJ
- Offices at Steeplechase Cancer Center in Somerville, NJ, and in South Plainfield, NJ
- Member of the Steeplechase Cancer Center Genitourinary, Lung, and Colorectal Multidisciplinary Committees

Hematologist-Oncologist, Georgia Cancer Specialists (GCS), 8/2005-12/2007

- Practiced in Marietta and Douglasville at Wellstar Health System Hospitals
- Lecturer at Annual GCS Protocol Seminar – Melanoma Guidelines
- Participation in STAT Clinic at Wellstar Kennestone Hospital – Prostate and Melanoma
- Development and Management of Tumor Board at Wellstar Douglas Hospital

Education & Training

Fellowship in Hematology/Oncology, Completed in 2005

Hahnemann University Medical Center, Philadelphia, PA

- Training Included On-Site Auto & Allogeneic Bone Marrow Transplantation
- Board Certified in Medical Oncology, Board Eligible in Hematology

Residency in Internal Medicine, Completed in 2002

Robert Wood Johnson Medical School at Camden

Cooper Hospital / University Medical Center, Camden, NJ

- Board Certified in Internal Medicine, 2003

Medical School, Graduated in 1999

Robert Wood Johnson Medical School, New Jersey

Masters of Public Health, Specialty in Health Policy & Management, Completed in 1995

Columbia University School of Public Health, New York

Bachelor of Science in Biology, Minor in Computer Science, Graduated in 1993

Columbia University, New York

Publications

Zak D, Styler MJ, **Rosenbluth JZ**, Brodsky I. Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma. Clin Adv Hematol Oncol. 2005 Apr; 3(4):297-9.

J. Z. Rosenbluth MD 6/20/14

Clinical and Research Experience

Served as principal investigator for both cooperative and industry-sponsored studies:

- 11/2008 – 01/2012: ACOSOG Z103 - A randomized phase II trial comparing exemestane, letrozole, and anastrozole in postmenopausal women with clinical stage II/III estrogen receptor-positive breast cancer.
- 12/2008 – 07/2011: N063D/ALTTO – Adjuvant Lapatinib and/or Trastuzumab treatment Optimisation Study – A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer.
- 11/2009 – 12/2010: C05012 – A Two-Arm, Non-Randomized, Multicenter, Phase 2 Study of VELCADE® (bortezomib) in Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin followed by Rituximab Maintenance in Patients with Relapsed Follicular Lymphoma

Served as sub-investigator for both cooperative and industry-sponsored studies since 2008

JAMA 6/20/14